Related Experiment Video
Updated: Jul 22, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Consensus on targeted drug therapy for spondyloarthritis
Xinping Tian1, Mengtao Li1, Shengyun Liu2
1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
This consensus provides guidance on targeted drug therapy for spondyloarthritis (SpA), a chronic inflammatory disease. It addresses challenges in identifying patient populations and standardizing treatment for improved quality of life.
Area of Science:
- Rheumatology and Immunology
- Clinical Medicine
Background:
- Spondyloarthritis (SpA) encompasses chronic inflammatory conditions affecting the spine and joints.
- SpA presents with heterogeneous manifestations and comorbidities, significantly impacting patient quality of life.
- Emerging targeted therapies offer new treatment avenues but require precise patient selection and standardized protocols.
Purpose of the Study:
- To develop a consensus on the targeted drug therapy for spondyloarthritis (SpA).
- To address critical issues in clinical application of targeted therapeutic drugs for SpA.
- To provide standardized guidance for rheumatologists and immunologists.
Main Methods:
- Evidence-based methodology was employed.
- International standards for consensus development were followed.
- Collaboration among multiple Chinese medical associations and committees was established.
Main Results:
- A consensus document on targeted drug therapy for SpA has been developed.
- The consensus aims to standardize the usage of new SpA medications.
- Guidelines focus on identifying appropriate patient populations for targeted treatments.
Conclusions:
- The consensus provides crucial guidance for the effective clinical application of targeted therapies in SpA.
- Standardized treatment protocols are essential for optimizing outcomes in SpA patients.
- This initiative supports improved management of SpA through evidence-based recommendations.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Therapy
Antianxiety Medications

